(0.04%) 5 519.25 points
(0.14%) 39 900 points
(0.08%) 19 767 points
(0.00%) $81.63
(0.50%) $2.83
(-0.26%) $2 338.30
(0.14%) $29.57
(0.58%) $1 007.60
(0.14%) $0.933
(-0.07%) $10.53
(0.05%) $0.789
(-0.85%) $87.25
0.00% $ 1.190
Live Chart Being Loaded With Signals
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer...
Stats | |
---|---|
Dzisiejszy wolumen | 146 709 |
Średni wolumen | 99 920 |
Kapitalizacja rynkowa | 78.40M |
EPS | $-0.300 ( Q1 | 2024-05-14 ) |
Następna data zysków | ( $-0.340 ) 2024-08-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.700 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00800 (0.68%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-06 | Smith David V | Buy | 45 642 | Stock Option (Right to Buy) |
2024-06-06 | Hunter Heidi | Buy | 45 642 | Stock Option (Right to Buy) |
2024-06-06 | Hirth Peter | Buy | 45 642 | Stock Option (Right to Buy) |
2024-06-06 | Glaub Kathleen Sereda | Buy | 45 642 | Stock Option (Right to Buy) |
2024-06-06 | Elling Christian E | Buy | 45 642 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
91.69 |
Last 87 transactions |
Buy: 67 969 052 | Sell: 5 187 181 |
Wolumen Korelacja
IO Biotech, Inc. Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
SSBI | 0.886 |
BLRX | 0.877 |
TROO | 0.877 |
SBAC | 0.875 |
CMAX | 0.875 |
SRNE | 0.873 |
CHTR | 0.873 |
ACIU | 0.871 |
FSBC | 0.87 |
LBRDK | 0.868 |
10 Najbardziej negatywne korelacje | |
---|---|
APXI | -0.882 |
TUR | -0.873 |
HYAC | -0.87 |
BOCN | -0.866 |
IGTA | -0.861 |
BSCO | -0.854 |
REAX | -0.853 |
OXSQ | -0.848 |
PRIM | -0.84 |
XBIT | -0.834 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
IO Biotech, Inc. Korelacja - Waluta/Towar
IO Biotech, Inc. Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-756 000 (0.00 %) |
EPS: | $-1.980 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-756 000 (0.00 %) |
EPS: | $-1.980 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-540 000 (0.00 %) |
EPS: | $-2.48 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-15.51 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
IO Biotech, Inc.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej